How I treat relapsed and/or refractory multiple myeloma

by Hans C. Lee, Claudio Cerchione
Published 2020-09-01

ESHAP versus GEMOX in Management of Relapsed or Refractory Lymphoma: A Prospective Randomized Study

by Hamdy Zawam, Wael Edesa, Sherif Alrefai, Rasha Salama, Ahmed Abdelhafeez
Published 2018-06-01

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

by Bhutani D, Zonder JA
Published 2017-07-01

Carfilzomib for relapsed and refractory multiple myeloma

by Groen K, van de Donk NWCJ, Stege CAM, Zweegman S, Nijhof IS
Published 2019-04-01

Bendamustine in patients with relapsed or refractory multiple myeloma

by Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian N N, Neumann F, Haas R, Kobbe G, Fenk R
Published 2010-01-01

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults

by Lee KJ, Chow V, Weissman A, Tulpule S, Aldoss I, Akhtari M
Published 2016-08-01

Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma

by Rita Assi, Nohad Masri, Iman Abou Dalle, Jean El-Cheikh, Hady Ghanem, Ali Bazarbachi
Published 2021-03-01

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab

by Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA
Published 2017-07-01

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor

by Nicola Sgherza, Paola Curci, Rita Rizzi, Rita Rizzi, Pellegrino Musto, Pellegrino Musto
Published 2021-09-01

Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib

by Shah A, Barrientos JC
Published 2021-03-01

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

by Joseph NS, Tai YT, Anderson KC, Lonial S
Published 2021-08-01

Clinical efficacy of sirolimus in treatment of relapsed and refractory autoimmune hemolytic anemia in adults

by YAN Hongju, WANG Ping, QUAN Yao, GAO Lei, LIU Yao
Published 2020-09-01

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey

by Uros Markovic, Uros Markovic, Alessandra Romano, Alessandra Romano, Vittorio Del Fabro, Claudia Bellofiore, Claudia Bellofiore, Anna Bulla, Anna Bulla, Marina Silvia Parisi, Salvatore Leotta, Massimo Gentile, Clotilde Cangialosi, Iolanda Vincelli, Giuseppe Mineo, Marco Rossi, Massimo Poidomani, Giuseppina Uccello, Cinzia Maugeri, Cinzia Maugeri, Donato Mannina, Vanessa Innao, Francesco Di Raimondo, Francesco Di Raimondo, Francesco Di Raimondo, Concetta Conticello
Published 2021-03-01

Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy

by Dima D, Dower J, Comenzo RL, Varga C
Published 2020-08-01

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

by Malandrakis P, Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E
Published 2020-07-01

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

by Cong Xu, Ting Liang, Fangrong Zhang, Jing Liu, Yunfeng Fu
Published 2021-05-01

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

by Du L, Zhang L, Li L, Li X, Yan J, Wang X, Fu X, Sun Z, Zhang X, Li Z, Wu J, Yu H, Chang Y, Zhou Z, Nan F, Wu X, Tian L, Zhang M
Published 2020-07-01

Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

by Patrick B. Johnston, Lauren C. Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren
Published 2018-05-01

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States

by Shah A, Tosh JC, Ambavane A, Nikolaou A, Hogea C, Samyshkin Y, Gorsh B, Maiese EM, Wang F
Published 2021-09-01